The findings presented here identify an enhancement of abnormal cell division from combination treatment with paclitaxel and the selective HDAC inhibitor ACY-241, though additional mechanisms likely also contribute to the observed anti-cancer activity in cellular and animal models of various solid tumor types. This evidence concerns the gene HDAC9 and cancer.